Focus Taiwan App
Download

NHI approves first patient for NT$49 million muscle atrophy drug

08/21/2023 05:16 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Taiwan's National Health Insurance (NHI) system has approved its first-ever patient to receive a one-time NT$49 million (US$1.53 million) drug for spinal muscular atrophy (SMA), which was added to a list of covered treatments earlier this month, an official said Monday.


(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.
    172.30.142.81